Details

Autor(en) / Beteiligte

• Maryam Ehteshami
• Brian J. Scarth
• Egor P. Tchesnokov
• Chandravanu Dash
• Stuart F. J. Le Grice
• Sabine Hallenberger
• Dirk Jochmans
• Matthias Götte

Titel

Mutations M184V and Y115F in HIV-1 Reverse Transcriptase Discriminate against “Nucleotide-competing Reverse Transcriptase Inhibitorsâ

Ist Teil von

• The Journal of biological chemistry, 2008-10, Vol.283 (44), p.29904

Ort / Verlag

American Society for Biochemistry and Molecular Biology

Erscheinungsjahr

2008

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Indolopyridones are potent inhibitors of reverse transcriptase (RT) of the human immunodeficiency virus type 1 (HIV-1). Although the structure of these compounds differs from established nucleoside analogue RT inhibitors (NRTIs), previous studies suggest that the prototype compound INDOPY-1 may bind in close proximity to the polymerase active site. NRTI-associated mutations that are clustered around the active site confer decreased, e.g. M184V and Y115F, or increased, e.g. K65R, susceptibility to INDOPY-1. Here we have studied the underlying biochemical mechanism. RT enzymes containing the isolated mutations M184V and Y115F cause 2–3-fold increases in IC 50 values, while the combination of the two mutations causes a >15-fold increase. K65R can partially counteract these effects. Binding studies revealed that the M184V change reduces the affinity to INDOPY-1, while Y115F facilitates binding of the natural nucleotide substrate and the combined effects enhance the ability of the enzyme to discriminate against the inhibitor. Studies with other strategic mutations at residues Phe-61 and Ala-62, as well as the use of chemically modified templates shed further light on the putative binding site of the inhibitor and ternary complex formation. An abasic site residue at position n , i.e. opposite the 3′-end of the primer, prevents binding of INDOPY-1, while an abasic site at the adjacent position n + 1 has no effect. Collectively, our findings provide strong evidence to suggest that INDOPY-1 can compete with natural deoxynucleoside triphosphates (dNTPs). We therefore propose to refer to members of this class of compounds as “nucleotide-competing RT inhibitors” (NcRTIs).